-
Drinking drinks as water for 5 years, the 28-year-old man was found to be suffering from diabetic ketoacid after unconscious
Time of Update: 2021-03-17
The family urgently dialed 120 to the emergency department of Southern Medical University Hospital of Integrated Traditional Chinese and Western Medicine, where he was diagnosed with type 2 diabetic ketoacidosis and acute renal failure.
-
"Pharmaceutical Speed Reading" Seymor Fly buys Henogen Ossecom injection tymo...
Time of Update: 2021-03-10
public information shows that Beckon Medical's PGT-A kit can screen embryos for normal development before implantation, which is the first and first high-volume gene sequencing kit approved by the State Drug Administration, marking the birth of China's PGT three-generation IVF "documented" industrial genetic testing market.
-
Internet hospitals may rely on physical medical institutions to settle medical insurance in accordance with the provisions
Time of Update: 2021-03-10
On January 8th the State Administration of Medical Security issued Order No. 2 of the State Administration of Medical Security, and the Interim Measures for the Administration of Medical Security In
-
"Not old medicine" was checked
Time of Update: 2021-03-10
A few days ago, according to relevant reports, the State Administration of Market Supervision and Administration issued a "letter on the detection of illegal operation of 'not old medicine'." The le
-
Who can "send a little red flower" to cancer patients in 2021?
Time of Update: 2021-03-10
In recent years, with the development of science, clinically began to use engineered immune cells to treat malignant blood system diseases (leukemia, etc.), while these "designed" immune cells have also been applied to liver cancer, lung cancer and other solid tumors in clinical research, the efficacy is very significant, this method is considered to be a milestone in the fight against cancer in humans.
-
FDA approves Johnson and Johnson Darzalex Faspro treatment for light chain starch...
Time of Update: 2021-03-10
The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro of Johnson and Johnson's Xi'an Jansen to treat newly diagnosed adult patients with light-chain amyloid degeneration.
-
More than a dozen cancer species usher in innovative therapies! Take stock of the anti-...
Time of Update: 2021-03-09
In April 2020, china's urethra skin cancer field ushered in an innovative treatment , the anti-PD-1 antibody drug in Baiji Shenzhou, which was approved for the treatment of patients with local late stage or metastatic PD-L1 high expression of urethra cancer who failed to receive platinum-containing chemotherapy, including new assisted or assisted chemotherapy within 12 months.
-
Heavy birth with patent expiring in 2021-2026...
Time of Update: 2021-03-08
Patent expiration is a key node in the life cycle of a drug and a challenge that all pharmaceutical companies are bound to face. the world every year a number of original research drug patents expir
-
Astellas Fumaric acid glytinib tablets have been approved for the treatment of recurring or refractic acute myelin...
Time of Update: 2021-03-08
- Accelerated approval after being included in the priority review and clinically urgent need for new drugs from abroad - Ginitinib is the first and currently the only FLT3 inhibitor approved by Chin
-
The FDA issues guidelines for biologics for 2021
Time of Update: 2021-03-08
CBER said it plans to complete guidance this year on interpreting gene therapy drug similarity in accordance with orphan drug regulations and update its small business compliance guidelines for human cells, tissues and cell-based and tissue-based products (HCT/Ps).
-
European Medicines Agency (EMA) Announces Summary of New Drug Authorizations for 2020 (II)
Time of Update: 2021-03-08
02 Special Cases Approval This year, the EMA approved five drugs that allow patients to obtain drugs that are not available under standard authorization, but this approval method does not provide access to complete drug data, and there may be potential risks such as the inability of certain rare diseases to be effectively evaluated, the safety and ability of collecting drugs to violate ethics, or gaps in the scientific field, so drugs are required to comply with special regulations.
-
Section 4 CAR-T therapy is approved by the FDA
Time of Update: 2021-03-08
The FDA has announced approval of the listing of the CAR-T treatment Breyanzi (lisocabtagene maraleucel), developed by Juno Therapeutics, a subsidiary of BMS, for the treatment of certain adult patients with large B-cell lymphoma who do not respond to at least two other systemic treatments or relapse after treatment.
-
AstraZenecom Dagrid China was approved
Time of Update: 2021-03-08
On February 4, AstraZeneca announced that Andaltang ® (common name: Dagley Net) has been officially approved in China for the treatment of patients with reduced blood test scores in adults (HFrEF, NYHA II-IV), reducing the risk of cardiovascular death and hospitalization for heart failure (hHF).
-
The application for listing of Trotsip for the injection of Baishi Meishiguibao was accepted for priority review
Time of Update: 2021-03-08
According to Insight Global's new drug library, Luspatercept was first approved by the U.S. FDA in November 2019 for the treatment of adult β-thalassemia patients who require regular infusion of red blood cells (RBCs), an adaptive disorder that is currently listed in Canada and the European Union.
-
2021 Tumor New Drug Data Card - Ginetinib
Time of Update: 2021-03-08
study in 2017 and has not yet submitted a listing application; Q3 adaptive gin is approved in China for the treatment of adult patients with FMS-like tyrosine kinase 3 (FLT3) mutation detected relapse (disease recurrence) or refractive (therapeutic resistance) acute myeloid leukemia (AML) using a fully validated detection method.
-
Five years later, 60% of patients are still in remission for the long-term effects of CAR-T therapy
Time of Update: 2021-03-07
60% of patients with B-cell lymphoma treated with Kymriah are still in remission after 5 years of treatment.
only one of the 18 patients who relapsed within a year of being treated with CAR-T cell therapy was genetically modified.
-
A non-"biological" man who had a biological child sued the hospital for compensation of 300,000
Time of Update: 2021-03-07
Wang and his wife believe that the test results of A hospital is not accurate, B hospital also did not further test, resulting in its years can not meet the desire to have a child with Wang's genes, causing serious economic losses and mental damage, and then sued the court to ask A, B hospital compensation for medical expenses, transportation, maintenance, moral damages, such as a total of 300,000 yuan.
-
2020 CRO average net profit industry first performance decline only three of the highest ...
Time of Update: 2021-03-07
the second half of this year, overseas customer orders grew faster and the company's capacity utilization rate and operating efficiency continued to improve, 20H2 revenue achieved strong growth (up more than 30%); Non-re current profit and loss impact, the market value of the underlying and un-listed shares invested in listed companies increased (affecting 1,794 million yuan) and non-cash book fair value losses (affecting 1,349 million yuan).
-
Will Chinese medicine be a good business?
Time of Update: 2021-03-07
In December 2020, the State Drug Administration's implementation opinion on promoting the innovation and development of traditional Chinese medicine heritage was noted in addition to the following good policies: exploring the introduction of real-world evidence to support the registration and listing of new Chinese medicines.
-
Review of the EU 2020 PRIME Priority Medicines Program
Time of Update: 2021-03-07
But not accepting a drug under the PRIME program does not mean that the drug should not continue to be developed, and the EMA has noted that "drugs that are not recognized by PRIME can still benefit patients by providing alternative treatment options for the disease." "One of last year's most notable PRIME identifies as Akero's efruxifermin (EFX) for the treatment of non-alcoholic fatty hepatitis (NASH).
